AU3236793A - Recombinant and chimeric antibodies to c-erbB-2 - Google Patents
Recombinant and chimeric antibodies to c-erbB-2Info
- Publication number
- AU3236793A AU3236793A AU32367/93A AU3236793A AU3236793A AU 3236793 A AU3236793 A AU 3236793A AU 32367/93 A AU32367/93 A AU 32367/93A AU 3236793 A AU3236793 A AU 3236793A AU 3236793 A AU3236793 A AU 3236793A
- Authority
- AU
- Australia
- Prior art keywords
- erbb
- recombinant
- chimeric antibodies
- chimeric
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US808462 | 1985-12-13 | ||
US80846291A | 1991-12-12 | 1991-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3236793A true AU3236793A (en) | 1993-07-19 |
Family
ID=25198826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU32367/93A Abandoned AU3236793A (en) | 1991-12-12 | 1992-12-04 | Recombinant and chimeric antibodies to c-erbB-2 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3236793A (en) |
WO (1) | WO1993012220A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993006217A1 (en) * | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
WO1994005332A2 (en) * | 1992-09-01 | 1994-03-17 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US6448077B1 (en) | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
CA2382100A1 (en) | 1999-08-27 | 2001-03-08 | Genentech, Inc. | Dosages for treatment with anti-erbb2 antibodies |
WO2001089566A1 (en) | 2000-05-19 | 2001-11-29 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
DK1819358T3 (en) | 2004-11-18 | 2014-10-27 | Imclone Llc | Antibodies to Vascular Endothelial Growth Factor Receptor-1 |
KR20190016616A (en) | 2005-01-21 | 2019-02-18 | 제넨테크, 인크. | Fixed dosing of her antibodies |
PL1850874T3 (en) | 2005-02-23 | 2014-03-31 | Genentech Inc | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2592156B1 (en) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
RU2504553C2 (en) | 2009-03-20 | 2014-01-20 | Дженентек, Инк. | Antibodies to her |
CN102421448A (en) | 2009-05-29 | 2012-04-18 | 霍夫曼-拉罗奇有限公司 | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
DK2536748T3 (en) | 2010-02-18 | 2014-10-13 | Genentech Inc | NEUREGULIN ANTAGONISTS AND ITS USE IN TREATMENT OF CANCER |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
JP5766296B2 (en) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components |
MX2014001766A (en) | 2011-08-17 | 2014-05-01 | Genentech Inc | Neuregulin antibodies and uses thereof. |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
CN104271761B (en) | 2011-11-30 | 2017-03-15 | 霍夫曼-拉罗奇有限公司 | Erbb3 mutation in cancer |
US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
BR112014024017A8 (en) | 2012-03-27 | 2017-07-25 | Genentech Inc | METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS |
EP2926142B2 (en) | 2012-11-30 | 2022-07-06 | F. Hoffmann-La Roche AG | Identification of patients in need of pd-l1 inhibitor cotherapy |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
-
1992
- 1992-12-04 AU AU32367/93A patent/AU3236793A/en not_active Abandoned
- 1992-12-04 WO PCT/US1992/010437 patent/WO1993012220A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1993012220A1 (en) | 1993-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3236793A (en) | Recombinant and chimeric antibodies to c-erbB-2 | |
AU4025193A (en) | Humanized C-erbB-2 specific antibodies | |
AU625613B2 (en) | Novel chimeric antibodies | |
AU645187B2 (en) | Freeze-dried preparation containing monoclonal antibody | |
AU5283893A (en) | Recombinant humanized anti-cytomegalovirus antibodies | |
SG48420A1 (en) | Humanized antibodies and uses thereof | |
AU5283793A (en) | Recombinant specific binding protein | |
AU4382193A (en) | BPI-immunoglobulin fusion proteins | |
AU3342689A (en) | Luminescent chimeric proteins | |
GB8800077D0 (en) | Novel chimeric antibodies | |
AU4618193A (en) | Humanized antibodies | |
IL100764A0 (en) | Monoclonal antibodies to elam-1 and their uses | |
GB9415380D0 (en) | Recombinant antibodies specific for tnf- | |
AU635996B2 (en) | Recombinant human anti-cd18 antibodies | |
AU3459593A (en) | Humanised antibody against hepatitis | |
GB9412166D0 (en) | Retargetting antibodies | |
AU3665293A (en) | Chimeric toxins binding to the GnRH receptor | |
AU4271793A (en) | Novel polypeptide | |
AU1025692A (en) | Novel chimeric antiidiotypic monoclonal antibodies | |
AU5647894A (en) | Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides | |
AU7796291A (en) | High affinity antibodies to small peptides | |
AU4889393A (en) | Human monoclonal anti-peptide antibody and DNA encoding thereof | |
AU6059194A (en) | Monoclonal antibodies to bovine cytokines | |
GB9220808D0 (en) | Antibody genes | |
EP0491351A3 (en) | Chimeric antibodies and their use |